Meeting NewsVideo

VIDEO: Oral treatment shows good visual improvement in newly diagnosed wet AMD patients

FORT LAUDERDALE, Fla. — At the Retina World Congress, Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic in Jacksonville, Florida, discusses first results of a phase 2a study of ALK4290 (Alkahest), now known as AKST4290, for the treatment of patients with newly diagnosed wet age-related macular degeneration.

FORT LAUDERDALE, Fla. — At the Retina World Congress, Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic in Jacksonville, Florida, discusses first results of a phase 2a study of ALK4290 (Alkahest), now known as AKST4290, for the treatment of patients with newly diagnosed wet age-related macular degeneration.

    See more from Retina World Congress